{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:36:24Z","timestamp":1794062184905,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230058"],"award-info":[{"award-number":["82230058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["CIFMS2022-I2M-C"],"award-info":[{"award-number":["CIFMS2022-I2M-C"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["T-B-067"],"award-info":[{"award-number":["T-B-067"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaut.2025.103423","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:15:30Z","timestamp":1745363730000},"page":"103423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer"],"prefix":"10.1016","volume":"153","author":[{"given":"Yalong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hewei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongnan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9432-1902","authenticated-orcid":false,"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103423_bib1","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"Bmj"},{"key":"10.1016\/j.jaut.2025.103423_bib2","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib3","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib6","first-page":"113","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med (N Y)"},{"key":"10.1016\/j.jaut.2025.103423_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg0675","article-title":"Clonally expanded, thyrotoxic effector cd8(+) t cells driven by il-21 contribute to checkpoint inhibitor thyroiditis","volume":"15","author":"Lechner","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jaut.2025.103423_bib9","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-024-02895-x","article-title":"Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis","volume":"30","author":"Thomas","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2025.103423_bib10","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103423_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"Ca-Cancer J. Clin."},{"key":"10.1016\/j.jaut.2025.103423_bib12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103423_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib14","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103423_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2025.103423_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jaut.2025.103423_bib17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jaut.2025.103423_bib18","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to pd-l1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaut.2025.103423_bib19","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","article-title":"Metronomic chemotherapy plus anti-pd-1 in metastatic breast cancer: a bayesian adaptive randomized phase 2 trial","volume":"30","author":"Mo","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jaut.2025.103423_bib20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/gutjnl-2022-327496","article-title":"Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study","volume":"72","author":"Zhang","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2025.103423_bib21","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41422-021-00562-1","article-title":"Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-cov-2(pos) subjects","volume":"31","author":"Yu","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.jaut.2025.103423_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nprot.2015.020","article-title":"Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm","volume":"10","author":"Zunder","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jaut.2025.103423_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/cyto.a.22271","article-title":"Normalization of mass cytometry data with bead standards","volume":"83","author":"Finck","year":"2013","journal-title":"Cytometry A"},{"key":"10.1016\/j.jaut.2025.103423_bib24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"Cytof workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaut.2025.103423_bib25","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2025.103423_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jaut.2025.103423_bib27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (ic-os) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.jaut.2025.103423_bib29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jaut.2025.103423_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00018-023-04715-w","article-title":"A review of the pleiotropic actions of the ifn-inducible cxc chemokine receptor 3 ligands in the synovial microenvironment","volume":"80","author":"Dillemans","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jaut.2025.103423_bib31","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1038\/s41467-019-12980-2","article-title":"Cxcr3 enables recruitment and site-specific bystander activation of memory cd8(+) t cells","volume":"10","author":"Maurice","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103423_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2015.02.009","article-title":"Cxcr3 chemokine receptor enables local cd8(+) t cell migration for the destruction of virus-infected cells","volume":"42","author":"Hickman","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103423_bib33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","article-title":"Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies","volume":"21","author":"Sullivan","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2025.103423_bib34","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the cxcr3 chemokine system is required for the efficacy of anti-pd-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103423_bib35","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.immuni.2019.05.013","article-title":"Cxcr3-cxcl9: it's all in the tumor","volume":"50","author":"Humblin","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103423_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"Cxcr3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jaut.2025.103423_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102498","article-title":"Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation","volume":"13","author":"Finke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaut.2025.103423_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1361097","article-title":"Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab","volume":"6","author":"Reuben","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jaut.2025.103423_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jhep.2022.03.039","article-title":"Uncoupling immune trajectories of response and adverse events from anti-pd-1 immunotherapy in hepatocellular carcinoma","volume":"77","author":"Chuah","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2025.103423_bib40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2025.103423_bib41","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"Mcinnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103423_bib42","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib43","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/1096-9896(200108)194:4<397::AID-PATH899>3.0.CO;2-S","article-title":"Differential expression of cxcr3 targeting chemokines cxcl10, cxcl9, and cxcl11 in different types of skin inflammation","volume":"194","author":"Flier","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.jaut.2025.103423_bib44","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41593-023-01432-2","article-title":"A genome-wide in vivo crispr screen identifies essential regulators of t cell migration to the cns in a multiple sclerosis model","volume":"26","author":"Kendirli","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jaut.2025.103423_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102846","article-title":"Ccr6-ccl20 axis as a therapeutic target for autoimmune diseases","volume":"20","author":"Meitei","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103423_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.imbio.2019.01.005","article-title":"The ccr6-ccl20 axis in humoral immunity and t-b cell immunobiology","volume":"224","author":"Lee","year":"2019","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaut.2025.103423_bib47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3389\/fimmu.2019.00333","article-title":"Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy","volume":"10","author":"Vilgelm","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103423_bib48","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","article-title":"Surface phenotype and antigenic specificity of human interleukin 17-producing t helper memory cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2025.103423_bib49","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1182\/blood-2015-01-622662","article-title":"Tc17 cells are a proinflammatory, plastic lineage of pathogenic cd8+ t cells that induce gvhd without antileukemic effects","volume":"126","author":"Gartlan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2025.103423_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1172\/JCI63681","article-title":"Il-17a secretion by cd8+ t cells supports th17-mediated autoimmune encephalomyelitis","volume":"123","author":"Huber","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jaut.2025.103423_bib51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jaut.2025.103423_bib52","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1038\/s41467-022-31229-z","article-title":"High-dimensional profiling reveals tc17 cell enrichment in active crohn's disease and identifies a potentially targetable signature","volume":"13","author":"Globig","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jaut.2025.103423_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nature10624","article-title":"Natural killer cells act as rheostats modulating antiviral t cells","volume":"481","author":"Waggoner","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103423_bib54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.it.2014.11.001","article-title":"Nk cells regulating t cell responses: mechanisms and outcome","volume":"36","author":"Crouse","year":"2015","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jaut.2025.103423_bib55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13075-022-02731-y","article-title":"Increased oxidative stress contributes to impaired peripheral cd56(dim)cd57(+) nk cells from patients with systemic lupus erythematosus","volume":"24","author":"Lu","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2025.103423_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of nk cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with sle","volume":"12","author":"Humbel","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103423_bib57","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2014.09.013","article-title":"Trail+ nk cells control cd4+ t cell responses during chronic viral infection to limit autoimmunity","volume":"41","author":"Schuster","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2025.103423_bib58","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4049\/jimmunol.180.2.850","article-title":"Regulatory nk cells suppress antigen-specific t cell responses","volume":"180","author":"Deniz","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2025.103423_bib59","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1084\/jem.186.10.1677","article-title":"Regulation of experimental autoimmune encephalomyelitis by natural killer (nk) cells","volume":"186","author":"Zhang","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2025.103423_bib60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jaut.2025.103423_bib61","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","article-title":"Lineage tracking reveals dynamic relationships of t cells in colorectal cancer","volume":"564","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2025.103423_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaut.2025.103423_bib63","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jaut.2025.103423_bib64","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jaut.2025.103423_bib65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016-2019 immunotox assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jaut.2025.103423_bib66","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jaut.2025.103423_bib67","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-pd-1 or anti-pd-l1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaut.2025.103423_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"Esmo Open"},{"key":"10.1016\/j.jaut.2025.103423_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.jaut.2025.103423_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jaut.2025.103423_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061225","article-title":"Non-invasive predictive biomarkers for immune-related adverse events due to immune checkpoint inhibitors","volume":"16","author":"Ponvilawan","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaut.2025.103423_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/imr.13249","article-title":"Biomarkers of immune checkpoint inhibitor response and toxicity: challenges and opportunities","volume":"318","author":"Goodman","year":"2023","journal-title":"Immunol. Rev."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112500068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089684112500068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T06:23:28Z","timestamp":1746167008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089684112500068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":72,"alternative-id":["S089684112500068X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103423","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic immune characteristics predicting toxicity to immune checkpoint inhibitors in patients with advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103423"}}